» Articles » PMID: 26352832

Correlation of Culture Positivity, PCR Positivity, and Burden of Borrelia Burgdorferi Sensu Lato in Skin Samples of Erythema Migrans Patients with Clinical Findings

Overview
Journal PLoS One
Date 2015 Sep 10
PMID 26352832
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Limited data are available regarding the relationship of Borrelia burden in skin of patients with erythema migrans (EM) and the disease course and post-treatment outcome.

Methods: We studied 121 adult patients with EM in whom skin biopsy specimens were cultured and analyzed by quantitative PCR for the presence of Borreliae. Evaluation of clinical and microbiological findings were conducted at the baseline visit, and 14 days, 2, 6, and 12 months after treatment with either amoxicillin or cefuroxime axetil.

Results: In 94/121 (77.7%) patients Borrelia was detected in skin samples by PCR testing and 65/118 (55.1%) patients had positive skin culture result (96.8% B. afzelii, 3.2% B. garinii). Borrelia culture and PCR results correlated significantly with the presence of central clearing and EM size, while Borrelia burden correlated significantly with central clearing, EM size, and presence of newly developed or worsened symptoms since EM onset, with no other known medical explanation (new or increased symptoms, NOIS). In addition, the logistic regression model for repeated measurements adjusted for time from inclusion, indicated higher Borrelia burden was a risk factor for incomplete response (defined as NOIS and/or persistence of EM beyond 14 days and/or occurrence of new objective signs of Lyme borreliosis). The estimated association between PCR positivity and unfavorable outcome was large but not statistically significant, while no corresponding relationship was observed for culture positivity.

Conclusions: Higher Borrelia burden in EM skin samples was associated with more frequent central clearing and larger EM lesions at presentation, and with a higher chance of incomplete response.

Citing Articles

Prevalence of Lyme Disease and Relapsing Fever spp. in Vectors, Animals, and Humans within a One Health Approach in Mediterranean Countries.

Koutantou M, Drancourt M, Angelakis E Pathogens. 2024; 13(6).

PMID: 38921809 PMC: 11206712. DOI: 10.3390/pathogens13060512.


Microbiologic Findings in a Cohort of Patients with Erythema Migrans.

Ruzic-Sabljic E, Maraspin V, Bogovic P, Rojko T, Ogrinc K, Jaklic M Microorganisms. 2024; 12(1).

PMID: 38258012 PMC: 10819209. DOI: 10.3390/microorganisms12010185.


Developing a Prospective Gestational Lyme Disease Study.

McLennan G, Dale S, Gillim L, Weinblatt V, Wallerstein R, Naides S Methods Mol Biol. 2024; 2742:259-278.

PMID: 38165628 DOI: 10.1007/978-1-0716-3561-2_18.


Determinants of persistent symptoms after treatment for Lyme borreliosis: a prospective observational cohort study.

Vrijmoeth H, Ursinus J, Harms M, Tulen A, Baarsma M, van de Schoor F EBioMedicine. 2023; 98:104825.

PMID: 38016860 PMC: 10755112. DOI: 10.1016/j.ebiom.2023.104825.


Lyme borreliosis diagnosis: state of the art of improvements and innovations.

Guerin M, Shawky M, Zedan A, Octave S, Avalle B, Maffucci I BMC Microbiol. 2023; 23(1):204.

PMID: 37528399 PMC: 10392007. DOI: 10.1186/s12866-023-02935-5.


References
1.
Liveris D, Wang G, Girao G, Byrne D, Nowakowski J, McKenna D . Quantitative detection of Borrelia burgdorferi in 2-millimeter skin samples of erythema migrans lesions: correlation of results with clinical and laboratory findings. J Clin Microbiol. 2002; 40(4):1249-53. PMC: 140402. DOI: 10.1128/JCM.40.4.1249-1253.2002. View

2.
Wormser G, Ramanathan R, Nowakowski J, McKenna D, Holmgren D, Visintainer P . Duration of antibiotic therapy for early Lyme disease. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2003; 138(9):697-704. DOI: 10.7326/0003-4819-138-9-200305060-00005. View

3.
Nowakowski J, Nadelman R, Sell R, McKenna D, Cavaliere L, Holmgren D . Long-term follow-up of patients with culture-confirmed Lyme disease. Am J Med. 2003; 115(2):91-6. DOI: 10.1016/s0002-9343(03)00308-5. View

4.
Stanek G, Strle F . Lyme borreliosis. Lancet. 2003; 362(9396):1639-47. DOI: 10.1016/S0140-6736(03)14798-8. View

5.
Steere A, Hutchinson G, Rahn D, Sigal L, Craft J, DeSanna E . Treatment of the early manifestations of Lyme disease. Ann Intern Med. 1983; 99(1):22-6. DOI: 10.7326/0003-4819-99-1-22. View